Citation: E. Celis, Identification and selection of T-cell epitopes derived from tumor-associated antigens for the development of immunotherapy for cancer, MED INTEL U, 24, 2000, pp. 1-16
Authors:
Maher, VE
Worley, BS
Contois, D
Smith, MC
Kelley, MJ
Stipanov, M
Khleif, SN
Goletz, T
van den Broeke, L
Mackall, C
Helman, LJ
Carbone, DP
Berzofsky, JA
Citation: Ve. Maher et al., Mutant oncogene and tumor suppressor gene products and fusion proteins created by chromosomal translocations as targets for cancer vaccines, MED INTEL U, 24, 2000, pp. 17-39
Authors:
Holt, GE
Velders, MP
Rudolf, MP
Small, LA
Provenzano, M
Weijzen, S
Da Silva, DM
Visser, M
ter Horst, SAJ
Brandt, RMP
Kast, WM
Citation: Ge. Holt et al., Critical dependence of the peptide delivery method on the efficacy of epitope focused immunotherapy, MED INTEL U, 24, 2000, pp. 56-72
Authors:
Seliger, B
Kono, K
Rongcun, Y
Kiessling, R
Citation: B. Seliger et al., Cytotoxic T cell epitopes and tissue distribution of the HER-2/neu proto-oncogene: Implications for vaccine development, MED INTEL U, 24, 2000, pp. 121-142
Authors:
Vissers, JLM
de Vries, IJM
Oosterwijk, E
Figdor, CG
Adema, GJ
Citation: Jlm. Vissers et al., Gp100 and G250: Towards specific immunotherapy employing dendritic cells in melanoma and renal cell carcinoma, MED INTEL U, 24, 2000, pp. 200-214